Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of combination or synergy of aspirin and trastuzumab in tumor therapy

A technology of trastuzumab and aspirin, applied in the field of tumor treatment, can solve the problems of high cost and limit the clinical application of trastuzumab, and achieve the effect of increasing the curative effect

Active Publication Date: 2018-03-23
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although trastuzumab can effectively improve the efficacy of HER2-positive breast cancer and gastric cancer, it is regrettable that only about 30% of HER2-positive breast and gastric cancer patients have significant effects, and most of them initially received trastuzumab Patients who respond to anti-therapy often develop drug resistance within 1 year, coupled with its high cost, which greatly limits the clinical application of trastuzumab

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination or synergy of aspirin and trastuzumab in tumor therapy
  • Application of combination or synergy of aspirin and trastuzumab in tumor therapy
  • Application of combination or synergy of aspirin and trastuzumab in tumor therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] This embodiment provides a drug combination for treating tumors, the drug combination includes trastuzumab, and aspirin for combined or synergistic administration with trastuzumab.

[0060] The drug combination provided in this example has a good therapeutic effect on tumors, especially HER2-positive tumors such as HER2-positive breast cancer or HER2-positive gastric cancer.

Embodiment 2

[0062] 1 Effect of aspirin combined with trastuzumab on the proliferation of HER2-positive breast cancer cells SKBR3

[0063] MTT method to detect cell proliferation

[0064] The normally grown SKBR3 cells were subcultured and inoculated in 96-well cell culture plates, with a volume of 200 μl per well, and the number of cells was 2×10 3 After culturing overnight, add 5 mM Aspirin (5 mM Aspirin), 15 μg / ml Trastuzumab (15 μg / ml Trastuzumab), 30 μg / ml Trastuzumab (30 μg / ml Trastuzumab) and two-drug combination (5mMAspirin +15μg / ml Trastuzumab, that is, the mass ratio of aspirin and trastuzumab is 60:1), (5mMAspirin+30μg / ml Trastuzumab, that is, the mass ratio of aspirin and trastuzumab is 60:2) culture medium The culture was continued, and the culture solution added with an equal volume of water for injection or DMSO was used as the control group (ie, the control group), and the cell proliferation was detected after 2 days. Prepare MTT at a concentration of 5 mg / ml, add 20 μl t...

Embodiment 3

[0071] Effect of aspirin combined with trastuzumab on apoptosis of HER2-positive breast cancer cells SKBR3

[0072] Detection of cell apoptosis by flow cytometry

[0073] The normal growing SKBR3 cells were subcultured and inoculated in culture dishes, and when the cell density reached about 80%, they were added with 5mM Aspirin (5mM Aspirin), 30μg / ml Trastuzumab (30μg / ml Trastuzumab) and the combination of the two drugs. (5mM Aspirin+30μg / ml Trastuzumab, that is, the mass ratio of aspirin to trastuzumab is 60:2) culture solution to continue to culture, to add equal volume of water for injection or DMSO culture solution as a control group (ie control group) , after 72h the cells were treated. Cells were digested and resuspended, and the number of cells was adjusted to 1×10 6 cells / ml, wash with PBS 2-3 times, add 500 μl buffer to suspend cells, then add 10 μl Annexin V-fluorescein isothiocyanate (Annexin V-FITC) and 10 μl PI, mix well, and incubate at room temperature in the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of aspirin and herceptin combination or synergy in oncotherapy, and relates to the technical field of oncotherapy. Relative to alone using of herceptin, aspirin is combined with the herceptin for medication, proliferation of HER2 positive tumor cells can be obviously restrained, and apoptosis of the HER2 positive tumor cells is promoted; and effect of anti-HER2 positive tumor of aspirin and herceptin combination for medication is better than effect of alone using of the herceptin. According to the application of aspirin and herceptin combination or synergy in oncotherapy, new application of the aspirin is discovered for the first time, and the aspirin helps to increase curative effect of the herceptin; and through the application of aspirin and herceptin combination or synergy in preparation of medicines used for treating tumors, theoretical basis is not only provided for anticancer effect of the aspirin in HER2 positive tumors, meanwhile, but also a new idea and a treatment mean are provided for treatment of tumors, especially HER2 positive tumors such as HER2 positive breast cancer or HER2 positive gastric cancer.

Description

technical field [0001] The present invention relates to the technical field of tumor treatment, in particular, relates to the combination or synergy of aspirin and trastuzumab in tumor treatment. Background technique [0002] At present, malignant tumors have become a major disease that threatens human health. Human Epidermal Growth Factor Receptor-2 (Her-2)-positive malignant tumors have strong infiltration, short disease-free survival and poor prognosis. [0003] HER2-positive breast cancer accounts for 20% to 30% of all breast cancers. In all molecular types of breast cancer, the time to distant metastasis and overall survival time of HER2-positive early breast cancer are both shorter. HER2-positive is a common molecular type of gastric cancer. According to statistics, about 20% of gastric cancers are HER2-positive. This type is more malignant than other types of gastric cancer. Therefore, the treatment and research of HER2-positive malignant tumors have attracted the a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/395A61K31/616A61P35/00
CPCA61K31/616A61K39/395A61K2300/00
Inventor 马骥张涛赵庆丽钟翠萍于晓辉吴伟强
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com